[New horizons of next generation chemotherapy for mycobacteriosis].
Stop TB Partnership (WHO) reported "Global TB Research and Development Projects" on the basis of the annual survey (October 2007): Basic Research: 9 projects, Drug Discovery: 32 projects, Preclinical: 8 projects, Clinical Testing: 13 projects are in proceeding. Among them, promising 7 of the new Anti-TB drug candidates: Nitroimidazopyran PA-824, Moxifloxacin MFLX, Gatifloxacin GFLX, Diaryl-quinoline TMC-207/R207910, Nitroimidazo-oxazole OPC-67683, Pyrrole LL-3858 and Diamine SQ-109 are in progress in clinical trial Phase I-III. In 2006, Working Group on New TB Drugs (WGND)/Stop TB Partnership and Global Alliance for TB Drug Development (GATB/TB Alliance) target: by 2010, 1-2 new drugs will be registered for TB; by 2015, 7 new drugs registered for TB indication, and treatment will be shortened regimens of 3-4 months with affordable and highly effective drugs.
Doi
Norio
N
Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama, Kiyose-shi, Tokyo 204-8533, Japan. ndoi@jata.or.jp
D000995:Antitubercular Agents / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents